vorinostat + bortezomib + doxorubicin + dexamethasone

The VBDD regimen is a four-drug combination therapy consisting of the histone deacetylase (HDAC) inhibitor vorinostat, the proteasome inhibitor bortezomib, the anthracycline doxorubicin, and the corticosteroid dexamethasone. This specific combination was investigated in the Phase I/II VERUMM study (Vorinostat in Elderly, Relapsed and Unfit Multiple Myeloma), an investigator-initiated trial conducted by the University Hospital Freiburg. Vorinostat, the primary investigational component, acts by inhibiting Class I and Class II HDAC enzymes (specifically HDAC1, HDAC2, HDAC3, and HDAC6), which leads to increased histone acetylation, altered gene expression, and the induction of cell cycle arrest and apoptosis. The regimen was designed to leverage the synergistic potential of epigenetic modulation alongside established myeloma therapies to overcome treatment resistance in heavily pretreated patients with relapsed or refractory multiple myeloma.

Other names

vorinostat-University Hospital Freiburg-multiple myelomaVERUMM regimenvorinostat, bortezomib, doxorubicin, and dexamethasone